ATE254287T1 - Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien - Google Patents
Verfahren zum nachweis beta-amyloid-reduzierenden-agenzienInfo
- Publication number
- ATE254287T1 ATE254287T1 AT98911801T AT98911801T ATE254287T1 AT E254287 T1 ATE254287 T1 AT E254287T1 AT 98911801 T AT98911801 T AT 98911801T AT 98911801 T AT98911801 T AT 98911801T AT E254287 T1 ATE254287 T1 AT E254287T1
- Authority
- AT
- Austria
- Prior art keywords
- amyloid
- reducing agents
- beta
- detecting beta
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000003638 chemical reducing agent Substances 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/821,876 US6221670B1 (en) | 1997-03-21 | 1997-03-21 | Methods to identify β-amyloid reducing agents |
| PCT/US1998/005363 WO1998043094A1 (en) | 1997-03-21 | 1998-03-19 | METHODS TO IDENTIFY β-AMYLOID REDUCING AGENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE254287T1 true ATE254287T1 (de) | 2003-11-15 |
Family
ID=25234504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98911801T ATE254287T1 (de) | 1997-03-21 | 1998-03-19 | Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6221670B1 (de) |
| EP (1) | EP0970379B1 (de) |
| JP (1) | JP2002508834A (de) |
| AT (1) | ATE254287T1 (de) |
| AU (1) | AU6567198A (de) |
| CA (1) | CA2284261A1 (de) |
| DE (1) | DE69819696T2 (de) |
| ES (1) | ES2212277T3 (de) |
| WO (1) | WO1998043094A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003528071A (ja) * | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| GB0010565D0 (en) * | 2000-05-02 | 2000-06-21 | Medical Res Council | Assay for acetylcholinesterase inhibitors |
| JP2004502665A (ja) * | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療する化合物 |
| US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| WO2003002122A1 (en) * | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| US20070213407A1 (en) * | 2001-06-29 | 2007-09-13 | Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc | Compounds to treat Alzheimer's disease |
| US6846641B2 (en) * | 2002-04-23 | 2005-01-25 | Agy Therapeutics, Inc. | In vitro ischemia model |
| EP1633786A4 (de) * | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus |
| GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| CL2007002908A1 (es) | 2007-10-09 | 2008-05-30 | Univ Concepcion | Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg |
| US20130046093A1 (en) * | 2011-08-18 | 2013-02-21 | Korea Institute Of Science And Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
| US9638548B2 (en) | 2012-05-07 | 2017-05-02 | Infineon Technologies Ag | Output switching systems and methods for magnetic field sensors |
| US10102992B2 (en) | 2014-02-25 | 2018-10-16 | Infineon Technologies Ag | Switching apparatus, switching system and switching method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
-
1997
- 1997-03-21 US US08/821,876 patent/US6221670B1/en not_active Expired - Lifetime
-
1998
- 1998-03-19 CA CA002284261A patent/CA2284261A1/en not_active Abandoned
- 1998-03-19 EP EP98911801A patent/EP0970379B1/de not_active Expired - Lifetime
- 1998-03-19 JP JP54579598A patent/JP2002508834A/ja not_active Ceased
- 1998-03-19 ES ES98911801T patent/ES2212277T3/es not_active Expired - Lifetime
- 1998-03-19 DE DE69819696T patent/DE69819696T2/de not_active Expired - Lifetime
- 1998-03-19 WO PCT/US1998/005363 patent/WO1998043094A1/en not_active Ceased
- 1998-03-19 AT AT98911801T patent/ATE254287T1/de not_active IP Right Cessation
- 1998-03-19 AU AU65671/98A patent/AU6567198A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6221670B1 (en) | 2001-04-24 |
| ES2212277T3 (es) | 2004-07-16 |
| DE69819696D1 (de) | 2003-12-18 |
| JP2002508834A (ja) | 2002-03-19 |
| DE69819696T2 (de) | 2004-09-16 |
| EP0970379B1 (de) | 2003-11-12 |
| AU6567198A (en) | 1998-10-20 |
| WO1998043094A1 (en) | 1998-10-01 |
| CA2284261A1 (en) | 1998-10-01 |
| EP0970379A1 (de) | 2000-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69819696D1 (de) | Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien | |
| DE69510342D1 (de) | Verfahren zum nachweis der permeabilität eines gegenstandes für sauerstoff | |
| DE69513248D1 (de) | Zusammensetzung, Verfahren und System zum Nachweis von Leukocyten, Esterasen oder Proteasen in einer Testprobe | |
| DE59405710D1 (de) | Mittel zur rauchsimulation für streulichtrauchmelder, verfahren zum abgleich von deren rauchempfindlichkeit und verwendung des mittels | |
| DE59601159D1 (de) | Verfahren zum gegenseitigen ausrichten von körpern und lagemesssonde hierfür | |
| DE60031548D1 (de) | Verfahren zum simultanen nachweis von beiden gliedern eines bindungspaares | |
| DE69128344D1 (de) | Vorrichtung und verfahren für elektrochemische messungen | |
| DE69827066D1 (de) | Verfahren und Vorrichtung zum Kompensieren von Mehrkanalechos | |
| DE59912155D1 (de) | Verfahren und vorrichtung zum statischen oder dynamischen ermitteln von sollwerten für bremskräfte oder bremsmomente | |
| DE3776302D1 (de) | Verfahren zur feststellung von gasen unter anwendung von chemisorption und physisorption. | |
| DE69019088D1 (de) | Verfahren und Apparat zur Erneuerung einer Elektrode eines Biosensors. | |
| DE69327775D1 (de) | Verfahren zur Vorbehandlung für Blutanalyse | |
| DE69417900D1 (de) | Vorrichtung und Verfahren zum schnellen und hochempfindlichen Erkennen und Zählen von Mikroorganismen mittels Fluoreszenz | |
| ATE278803T1 (de) | Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte | |
| DE3575621D1 (de) | Verfahren und anordnung zum kennzeichnen und erkennen von gegenstaenden. | |
| DE3674453D1 (de) | Verfahren und vorrichtung zur zerstoerungsfreien pruefung ferromagnetischer koerper. | |
| DE59707425D1 (de) | Verfahren und teststreifen zur bestimmung eines analyten | |
| DE69413042D1 (de) | Verfahren und vorrichtung zum feststellen der verschiebung eines gegenstandes | |
| DE69020355D1 (de) | Verfahren zur befestigung eines elastischen streifens. | |
| DE69521622D1 (de) | System und verfahren zur sprachverarbeitung mittels multipuls-analyse | |
| DE69504949T3 (de) | Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs | |
| DE69208108D1 (de) | Verfahren und Vorrichtung zur Prüfung von Gasleckage | |
| DE69320457D1 (de) | Verfahren und anordnung für bioaffinitätsassays | |
| DE69837575D1 (de) | Vorrichtung und Verfahren zur Inkubation von Teststreifen | |
| DE59812865D1 (de) | Verfahren zur Reduzierung von Störungen bei der Übertragung eines elektrischen Nachrichtensignals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |